Wall Street analyst estimates for Belite Bio, Inc (BLTE): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-09 | $-0.79 | ||
| 2026-08-12 | $-0.70 | $-0.73 | +4.1% |
| 2026-05-20 | $-0.34 | $-0.60 | +43.3% |
| 2026-03-02 | $-0.38 | $-0.56 | +32.1% |
| 2025-11-10 | $-0.65 | $-0.53 | -22.6% |
| 2025-08-11 | $-0.50 | $-0.47 | -6.4% |
| 2025-05-13 | $-0.45 | $-0.36 | -25.0% |
| 2025-03-17 | $-0.32 | $-0.30 | -6.7% |
Valuation Ratios
| Price / Book | 8.75 |
| EV / EBITDA | -64.97 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $3.7M | $7.4M | $8.9M | $24.8M | $29.9M | $45.4M |
| Selling, General & Admin | $2.1M | $2.4M | $4.0M | $6.8M | $10.1M | $38.8M |
| Operating Expenses | $5.7M | $9.8M | $12.8M | $31.7M | $40.0M | $84.2M |
| Operating Income | -$5.7M | -$9.8M | -$12.8M | -$31.7M | -$40.0M | -$84.2M |
| EBITDA | -$5.7M | -$9.6M | -$12.4M | -$31.2M | -$35.7M | -$77.1M |
| Interest Expense | $21000 | 0 | $16000 | $25000 | $20000 | 0 |
| Pre-tax Income | -$5.8M | -$9.7M | -$12.6M | -$31.6M | -$36.1M | -$77.6M |
| Income Tax | $1000 | 0 | 0 | $9000 | $6000 | 0 |
| Net Income | -$5.8M | -$9.7M | -$12.6M | -$31.6M | -$36.1M | -$77.6M |
| EPS | $-0.62 | $-0.40 | $-0.63 | $-1.19 | $-1.18 | $-2.31 |
| EPS (Diluted) | $-0.62 | $-0.40 | $-0.63 | $-1.19 | $-1.18 | $-2.31 |
| Shares Outstanding (Diluted) | $9.2M | $24.1M | $20.0M | $26.6M | $30.5M | $33.5M |
Price
| Price | $169.21 |
| Market Cap | $6.8B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACAD · ADMA · ARQT · CRNX · DYN · LGND · MIRM
Explore sector: Healthcare · Biotechnology
More sections of BLTE: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks